London, UK – 24 January 2024. A clinical validation study of Digistain in 801 patients with ER-positive, HER2-negative early breast cancer (median follow-up 12.7 years)
We are the finalists of Health Tech Challengers 2023. Join us at the event
We take pride in our involvement with SpinOff Bulgaria, a program dedicated to nurturing innovation and promoting entrepreneurial spirit.
Delighted to have been selected by EIT Health as a semi-finalist.
LONDON – 19 JULY 2023: A health-economic study commissioned by the UK government modelled potential NHS savings from using Digistain under stated assumptions. The study,
We are presenting a poster at the ESMO Breast Cancer Annual Congress (#ESMOBreast23) from 11-13 May in Berlin. The poster reports the prognostic performance of
Team Digistain with Prof Sir Mike Dixon OBE at the American Society of Breast Surgeons Annual Symposium this year where we were honored to be
Honoured today to be offered a place on NHS Oxford’s UK Access Program! #digitalhealth #accelerator
Delighted to be shortlisted as a finalist at the Medilink Business Awards 2023 for not one but two categories! Advances in Digital Health and for
Thankful for the opportunity to unveil our latest clinical study at San Antonio Breast Cancer Symposium this week! #sabcs2022 #oncology #breastcancer
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.
